- Trials with a EudraCT protocol (32)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
32 result(s) found for: Intelligence tests.
Displaying page 1 of 2.
EudraCT Number: 2004-003941-42 | Sponsor Protocol Number: B4Z-SO-LY15 | Start Date*: 2005-02-11 |
Sponsor Name:Eli Lilly Sweden AB | ||
Full Title: A Randomised, Double Blind Placebo Controlled Study of the Broader Efficacy of Atomoxetine Hydrochloride in the Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in Swedish Children and ... | ||
Medical condition: Attention-Deficit/Hyperactivity Disorder (ADHD) is a common psychiatric disorder that has its onset in childhood, and that is estimated to occur in 3% to 6% of school-age children. ADHD is characte... | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: SE (Completed) | ||
Trial results: View results |
EudraCT Number: 2006-001471-37 | Sponsor Protocol Number: B4Z-SB-LYDW | Start Date*: 2006-10-31 |
Sponsor Name:Lilly Deutschland GmbH, Teichweg 3, 35396 Gießen | ||
Full Title: A Randomized, Double-Blind Comparison of Atomoxetine versus Placebo in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder and Comorbid Oppositional Defiant Disorder | ||
Medical condition: Children and adolescents with ADHD (Attention-Deficit/Hyperactivity Disorder) and comorbid ODD (Oppositional Defiant Disorder). | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2005-005701-32 | Sponsor Protocol Number: B4Z-IT-LYDS | Start Date*: 2006-03-07 | |||||||||||
Sponsor Name:ELI LILLY | |||||||||||||
Full Title: An Open-Label Study of the Efficacy of Atomoxetine Hydrochloride on Quality of Life of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder with or without comorbid conditions | |||||||||||||
Medical condition: Child or adolescent patients with Attention-Deficit/ Hyperactivity Disorder ADHD | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-005971-18 | Sponsor Protocol Number: 13-617 | Start Date*: 2014-01-24 |
Sponsor Name:University Medical Center Utrecht | ||
Full Title: TimeToStop (TTS) Trial, A randomised controlled trial of early versus late antiepileptic drug withdrawal after pediatric epilepsy surgery | ||
Medical condition: We will investigate possible cognitive benifits of early antiepileptic drug withdrawal after pediatric epilepsy surgery. The concerning medical condition is refractory epilepsy | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: NL (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2017-002803-81 | Sponsor Protocol Number: TREX | Start Date*: 2020-04-03 | |||||||||||
Sponsor Name:IRCCS ISTITUTO GIANNINA GASLINI | |||||||||||||
Full Title: Neurodevelopmental outcome after standard dose sevoflurane versus low-dose sevoflurane/dexmedetomidine/remifentanil anaesthesia in young children | |||||||||||||
Medical condition: Children under the age of 2 years having surgery lasting at least 2 hours | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-005512-27 | Sponsor Protocol Number: B4Z-EW-LYDY | Start Date*: 2007-03-12 | |||||||||||
Sponsor Name:Eli Lilly and Company | |||||||||||||
Full Title: A Randomized, Controlled, Open-Label Study of the Long-Term Impact on Functioning using Atomoxetine Hydrochloride Compared to Other Early Standard Care in the Treatment of Attention-Deficit/Hyperac... | |||||||||||||
Medical condition: Attention Deficit Hyperactivity Disorder | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) BE (Completed) NO (Ongoing) IE (Completed) NL (Not Authorised) GB (Completed) IT (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-004088-31 | Sponsor Protocol Number: B4Z-XM-LYDM | Start Date*: 2005-04-19 | |||||||||||
Sponsor Name:Lilly S.A. | |||||||||||||
Full Title: A Randomized Double-Blind, Placebo-Controlled Clinical Trial of Efficacy and Safety of Atomoxetine up to 12 weeks in Newly Diagnosed Children and Adolescents Outpatients with Attention-Deficit/Hyp... | |||||||||||||
Medical condition: Attention-Deficit/Hyperactivity Disorder | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-000191-24 | Sponsor Protocol Number: B4Z-UT-LYEL | Start Date*: 2008-05-09 | |||||||||||
Sponsor Name:Eli Lilly Nederland | |||||||||||||
Full Title: An Open Label Pilot Study of Atomoxetine Hydrochloride in Adolescents with Attentioin-Deficit/Hyperactivity Disorder and Comorbid Cannabis Abuse | |||||||||||||
Medical condition: Attention Deficit Hyperactivity Disorder | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-004739-19 | Sponsor Protocol Number: OSU6162aSAH | Start Date*: 2017-06-16 |
Sponsor Name:Oslo University Hospital | ||
Full Title: OSU6162 IN THE TREATMENT OF FATIGUE AND OTHER NEUROPSYCHOLOGICAL SEQUELAE AFTER ANEURYSMAL SUBARACHNOIDAL HEMORRHAGE - A DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED STUDY | ||
Medical condition: Fatigue and neuropsychological dysfunction after aneurysmal brain hemorrhage | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NO (Completed) | ||
Trial results: View results |
EudraCT Number: 2020-002329-27 | Sponsor Protocol Number: ETLAS-2 | Start Date*: 2020-12-10 | ||||||||||||||||
Sponsor Name:Herlev Gentofte Hospital | ||||||||||||||||||
Full Title: Improving cerebral blood flow and cognition in patient with cerebral small vessel disease. The ETLAS-2 Trial. | ||||||||||||||||||
Medical condition: Cerebral small vessel disease and stroke. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DK (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-011426-33 | Sponsor Protocol Number: B4Z-EW-LYEN | Start Date*: 2009-10-13 | |||||||||||
Sponsor Name:Lilly S.A. | |||||||||||||
Full Title: Evaluación del Efecto de las Dosis Omitidas (Días Off) de la Medicación Diaria en Pacientes con una Farmacoterapia Estable para el TDAH Recibiendo Atomoxetina o Metilfenidato OROS: Un Estudio Clín... | |||||||||||||
Medical condition: Trastorno por Deficit de Atencion-Hiperactividad (TDAH) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) NL (Completed) SE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-000206-28 | Sponsor Protocol Number: SB-318-1502 | Start Date*: 2018-08-14 | |||||||||||
Sponsor Name:Sangamo Therapeutics, Inc. | |||||||||||||
Full Title: A Phase 1/2, Multicenter, Open-Label, Single-Dose, Dose-Ranging Study to Assess the Safety and Tolerability of SB-318, a rAAV2/6-based Gene Transfer in Subjects with Mucopolysaccharidosis I (MPS I) | |||||||||||||
Medical condition: Mucopolysaccharidosis type I (MPS I) | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-000192-33 | Sponsor Protocol Number: SB-913-1602 | Start Date*: 2018-08-17 | |||||||||||
Sponsor Name:Sangamo Therapeutics, Inc. | |||||||||||||
Full Title: A Phase 1/2, Multicenter, Open-label, Single-dose, Dose-ranging Study to Assess the Safety and Tolerability of SB-913, a rAAV2/6-based Gene Transfer in Subjects with Mucopolysaccharidosis II (MPS II) | |||||||||||||
Medical condition: Mucopolysaccharidosis type II (MPS II) | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-002326-36 | Sponsor Protocol Number: 2016-858 | Start Date*: 2016-11-09 | ||||||||||||||||
Sponsor Name:Region Hovedstadens psykiatriske hospital | ||||||||||||||||||
Full Title: Effects of erythropoietin (EPO) on cognitive side-effects of electroconvulsive therapy (ECT) (EPO-T) | ||||||||||||||||||
Medical condition: Unipolar/bipolar depression | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DK (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2010-018518-56 | Sponsor Protocol Number: E2007-G000-235 | Start Date*: 2010-10-11 |
Sponsor Name:Eisai Limited | ||
Full Title: A Randomized, Double-blind, Placebo-controlled, Parallel-group Study With an Open-label Extension Phase to Evaluate the Effect of Perampanel (E2007) on Cognition, Growth, Safety, Tolerability, and ... | ||
Medical condition: Inadequately controlled partial onset seizures | ||
Disease: | ||
Population Age: Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: LV (Completed) ES (Completed) BE (Completed) HU (Completed) CZ (Completed) | ||
Trial results: View results |
EudraCT Number: 2018-003180-54 | Sponsor Protocol Number: 20275 | Start Date*: 2020-04-25 | |||||||||||
Sponsor Name:Bayer AG | |||||||||||||
Full Title: An extension study to evaluate the long-term outcomes of subjects who received treatment for retinopathy of prematurity in Study 20090 | |||||||||||||
Medical condition: Retinopathy of prematurity | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Trial now transitioned) SE (Trial now transitioned) GB (GB - no longer in EU/EEA) DE (Completed) AT (Prematurely Ended) HU (Completed) ES (Ongoing) NL (Prematurely Ended) PT (Ongoing) GR (Trial now transitioned) BE (Trial now transitioned) SK (Trial now transitioned) BG (Trial now transitioned) LV (Completed) EE (Completed) IT (Trial now transitioned) PL (Completed) RO (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-000419-98 | Sponsor Protocol Number: B4Z-US-LYEI | Start Date*: 2021-12-13 | ||||||||||||||||
Sponsor Name:Eli Lilly and Company | ||||||||||||||||||
Full Title: Neurophysiology of Attention-Deficit/Hyperactivity Disorder (ADHD) and Comorbid Dyslexia: Functional Magnetic Resonance Imaging (fMRI) Measures of Brain Activation During Attention and Reading Tas... | ||||||||||||||||||
Medical condition: Attention Deficit Hyperactivity Disorder, Dyslexia. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: Outside EU/EEA | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2011-004854-25 | Sponsor Protocol Number: SPON803-10 | Start Date*: 2012-01-10 | |||||||||||
Sponsor Name:Cardiff University | |||||||||||||
Full Title: TRON: A randomised, double blind, placebo-controlled study of RAD001 (Everolimus) in the treatment of neurocognitive problems in tuberous sclerosis. | |||||||||||||
Medical condition: Tuberous Sclerosis Complex (TSC) | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-005742-37 | Sponsor Protocol Number: 06/AN/02 | Start Date*: 2007-01-26 | |||||||||||
Sponsor Name:NHS Glasgow and Clyde / University of Glasgow | |||||||||||||
Full Title: Randomised clinical trial of the effects of total intravenous anaesthesia (TIVA: propofol) versus volatile anaesthesia (sevoflurane-N20 induction and isoflurane-N20 maintenance) on children’s post... | |||||||||||||
Medical condition: Dental caries | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-003284-19 | Sponsor Protocol Number: CTU/2013/073 | Start Date*: 2017-01-24 |
Sponsor Name:University College London | ||
Full Title: DEpletion of Serum amyloid P component In Alzheimer’s Disease: DESPIAD. Double-blind placebo controlled randomised phase IIb trial of SAP depletion by CPHPC in mild Alzheimer’s disease. | ||
Medical condition: Alzheimer's disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
